MimiVax awarded Orphan Drug Designation by US FDA for SurVaxM to treat glioblastoma patients

Roswell Park

  • Immunotherapy vaccine SurVaxM to be added to FDA registry of orphan drugs
  • Unique vaccine being studied as treatment for glioblastoma, other cancers
  • Phase II clinical trial in glioblastoma underway; larger study anticipated

Read Full Article

More news